EFdA-TP (tetraammonium)

EFdA-TP tetraammonium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetraammonium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT) . EFdA-TP tetraammonium inhibits HIV-1 RT with multiple mechanisms[1]. EFdA-TP (tetraammonium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

UNSPSC

12352005

Target

DNA/RNA Synthesis; HIV; Reverse Transcriptase

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Purity

98.03

Solubility

10 mM in DMSO

Smiles

O=[P](O[P](O[P](O)(O)=O)(O)=O)(O)OC[C@]1(O[C@@](C[C@@H]1O)([H])N2C3=NC(F)=NC(N)=C3N=C2)C#C.N.N.N.N

Molecular Formula

C12H27FN9O12P3

Molecular Weight

601.32

References & Citations

[1]Martin Markowitz, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. Curr Opin HIV AIDS. 2018 Jul;13 (4) :294-299.|[2]Eleftherios Michailidis, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289 (35) :24533-48.